Dolphin Medical (526504)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At ₹1.85, Dolphin Medical trades at only 0.29 times its book value of ₹6.49. On paper, that looks like a classic Graham cigar-butt: a ₹3 Cr market cap against a far larger stated net worth. But I have to ask the harder question — what is this business actually earning? The latest quarter shows sales of ₹0 Cr and net profit of ₹0 Cr. This is not a going concern generating income; it is a non-operating shell or a company in hibernation. Sales have declined 12.5%, returns on equity and capital are slightly negative at -0.16% and -0.18%, and the 100% profit growth figure is an arithmetic illusion from a negligible base. The Piotroski F-score of 5/9 suggests only average financial health, not a strong balance sheet. There is no dividend, promoter holding is not disclosed, and the price is below the 52-week range low, so the market is treating this with deep suspicion. Ben Graham would caution me to buy assets only if they are real, recoverable, and not at the mercy of management. At ₹1.85, the margin of safety appears wide, but a book value that earns nothing can quickly erode. I cannot call this a wonderful business, and I cannot project earnings. What remains is an asset play — a possible bargain if the underlying net assets are genuinely worth close to ₹6.49 per share and can be unlocked. Otherwise, investors are simply holding a pawn ticket on a non-income-producing asset.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer